City
Epaper

Global study on Covid-19 origins finds lab origin 'extremely unlikely'

By IANS | Updated: March 31, 2021 16:00 IST

Beijing, March 31 The WHO-China joint team on the global study of the origins of Covid-19 found that ...

Open in App

Beijing, March 31 The WHO-China joint team on the global study of the origins of Covid-19 found that introduction through a laboratory incident is "extremely unlikely," a senior Chinese expert of the joint team said on Wednesday.

Experts from the World Health Organization and China jointly conducted the research in China and made an assessment of the likelihood of possible pathways, according to Liang Wannian, head of the Chinese side of the joint team, the Xinhua news agency reported.

According to a report on the China Part of the study, Covid-19 introduction through an intermediate host is "likely to very likely," introduction through cold/food chain products is "possible," and introduction through a laboratory incident is "extremely unlikely," Liang said.

( With inputs from IANS )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Liang wannianchinabeijingXinhuaWorld Health OrganizationWhoWorld healthU of u healthFinance and healthNational public health organizationKati assembly
Open in App

Related Stories

International'Illegal Military Operations': China Accuses US and Israel of Strait of Hormuz Crisis

NationalDelhi Government Orders Removal of 2.5 Lakh Chinese CCTV Cameras Over Security Concerns

InternationalChina: Four Dead, Nine Injured After Explosion at Highway Tunnel Construction Site in Chongqing

InternationalChina: Casualties Feared After Bulldozer Runs Over Crowd in Beijing Market (Watch Video)

MumbaiMumbai: DRI Seizes Restricted Goods Worth ₹9.25 Crore; Two Firm Owners Arrested

Health Realted Stories

HealthGujarat: Hotels, eateries fined for paneer display violations; 615 kg of substandard food destroyed

HealthMinistry of Social Justice clocks highest-ever Rs 11,810 crore expenditure in FY26

HealthIndia to boost biosimilar insulin, CGM manufacturing as Global South looks for support

HealthIndia clocks unprecedented foodgrain output, boosts institutional support to farmers

HealthIndia tightens watch on GLP-1 drugs amid safety and misuse concerns